Medicine
Vyepti 100 mg/1 mL injection
Vyepti 100 mg/1 mL injection is a prescription medicine containing Eptinezumab for intravenous use, marketed by Lundbeck Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to…
Key facts
- Active ingredient (INN)
- Eptinezumab
- Brand
- Vyepti
- Strength
- 100 mg/1 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 1 vial of 1 mL
- Marketing authorisation holder
- Lundbeck Pharmaceuticals
- Manufacturer
- Lundbeck Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until time of use. Do not freeze or shake.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N02CD Antimigraine, subgroup N02CD
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 21 February 2020
- Identifiers
- RxCUI 2283049, 2283054DailyMed set ID 79065861-6aa5-4d1f-829f-3a6471286b36NDC 67386-130Application BLA761119
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-dose in 1 carton / 1 mL in 1 vial, single-dose | 67386-130-51 | Lundbeck Pharmaceuticals | 21 February 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Eptinezumab is a calcitonin gene-related peptide antagonist indicated for the preventive treatment of migraine in adults. It is available as injection for intravenous use. MedsAcross supplies Eptinezumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about EptinezumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Vyepti prescribing information (Lundbeck Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Vyepti: European public assessment report (EPAR) · European Medicines Agency
Need Vyepti 100 mg/1 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.